Minerva Neurosciences, Inc. (NERV) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6033802058
Minerva Neurosciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -15.10 m USD |
| EBIT | -294.37 m USD |
| Net income | -293.42 m USD |
| Diluted EPS – continuing operations | -34.67 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
More stocks
- FIRST KEYSTONE CORP (FKYS)
- Talisker Resources Ltd (TSK.TO)
- Kolon Life Science Inc (102940.KQ)
- TUL Corporation (6150.TWO)
- Detection Technology OY (DETEC.HE)
- Silver One Resources Inc (SVE.V)
- Elektroimportoren As (ELIMP.OL)
- PT Mandiri Herindo Adiperkasa Tbk (MAHA.JK)
- Globe Union Industrial Corp (9934.TW)
- Kyung Nong Corporation (002100.KS)
- Samhwa Paint (000390.KS)
- RTX A/S (RTX.CO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.